
## Eddie Lau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2999311/publications.pdf Version: 2024-02-01



FODIELAU

#	Article	IF	CITATIONS
1	Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose–response relationship. Radiotherapy and Oncology, 2016, 118, 540-546.	0.6	60
2	Imaging of nonthrombotic pulmonary embolism: Biological materials, nonbiological materials, and foreign bodies. European Journal of Radiology, 2013, 82, e120-e141.	2.6	53
3	TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. BMC Cancer, 2018, 18, 1030.	2.6	50
4	Prostateâ€specific membrane antigenâ€positron emission tomography/computed tomography (PSMAâ€PET/CT)â€guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a singleâ€institution experience and review of the published literature. BJU International, 2019, 124, 19-30.	2.5	46
5	Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1348-1355.	6.4	31
6	A prospective study comparing digital breast tomosynthesis with digital mammography in surveillance after breast cancer treatment. European Journal of Cancer, 2016, 61, 122-127.	2.8	25
7	Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. Leukemia and Lymphoma, 2012, 53, 1889-1895.	1.3	23
8	Utility of positron emission tomography/computed tomography for nodal staging of cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2014, 35, 66-69.	1.3	19
9	Safety and cost analysis of an 18FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation. Oral Oncology, 2015, 51, 529-535.	1.5	19
10	Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods Journal of Nuclear Medicine, 2021, 62, jnumed.120.254508.	5.0	19
11	High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1330-1336.	6.4	17
12	Neurolymphomatosis: <scp>MRI</scp> and <sup>18</sup> <scp>FDG</scp> â€ <scp>PET</scp> features. Journal of Medical Imaging and Radiation Oncology, 2016, 60, 92-95.	1.8	17
13	Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma. PLoS ONE, 2018, 13, e0202387.	2.5	15
14	Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1596-1604.	6.4	15
15	Prolonged Remission in a Patient With Nasopharyngeal Carcinoma With a Solitary Bone Metastasis. Journal of Clinical Oncology, 2011, 29, e135-e137.	1.6	13
16	What, where and why: exploring fluorodeoxyglucose-PET's ability to localise and differentiate infection from cancer. Current Opinion in Infectious Diseases, 2017, 30, 552-564.	3.1	12
17	The clinical utility of fluorodeoxyglucoseâ€positron emission tomography for investigation of fever in immunocompromised children. Journal of Paediatrics and Child Health, 2018, 54, 487-492.	0.8	9
18	Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease. Journal of Thoracic Disease, 2019, 11, 1756-1764.	1.4	8

Eddie Lau

#	Article	IF	CITATIONS
19	Breast ultrasound in breast cancer surveillance; incremental cancers found at what cost?. Breast, 2020, 54, 272-277.	2.2	6
20	Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: BriefÂReport. Clinical Lung Cancer, 2020, 21, e57-e60.	2.6	5
21	Ventilation perfusion lung SPECT / CT in pregnancy during COVID â€19. Internal Medicine Journal, 2020, 50, 1588-1590.	0.8	5
22	Recognising pitfalls in assessment of tumours by diffusionâ€weighted <scp>MRI</scp> : A pictorial essay. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 188-194.	1.8	4
23	Value of Bone Scans in Work-up of Patients With Hepatocellular Carcinoma for Liver Transplant. Transplantation Direct, 2018, 4, e408.	1.6	3
24	PET/CT findings within the contralateral tonsil following unilateral tonsillectomy. Laryngoscope, 2016, 126, 2480-2483.	2.0	2
25	ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414. Neuro-Oncology, 2018, 20, vi24-vi24.	1.2	2
26	Defining primary anal cancer tumour volume on FDG–PET – an initial assessment of semi–automated methods. International Journal of Radiology & Radiation Therapy, 2021, 8, 1-7.	0.1	1
27	Unusual location of recurrent mantle cell lymphoma on fluorodeoxyglucose-positron emission tomography despite complete metabolic resolution of previous sites of disease. World Journal of Nuclear Medicine, 2020, 19, 277.	0.5	0